Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 20 von 20, Suchdauer: 0.69s

1
PD-L1-Expression im Primärtumor vs. Metastase in Proben der Phase-III-Studie MYSTIC bei 1st-Line metastasiertem NSCLC

von Wehler, T ; Reinmuth, N ; Boothman, AM ; et al.

Pneumologie ; 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. ; ISSN 1438-8790
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

2
Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)

von Planchard, D ; Garassino, MC ; Paz-Ares, L ; et al.
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

3
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial

von Paz-Ares, L ; Spira, A ; Raben, D ; et al.
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

4
The implementation of a hepatitis C testing service in community pharmacies: I-COPTIC consensus statement

von Cook C ; Reid L ; Elsharkawy AM ; et al.

Public Health, July 2024
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

5
Unraveling systemic responses to NQO1-activated IB-DNQ and Rucaparib single and dual agent therapy in triple-negative breast cancers.

von Runnebohm AM ; Wijeratne HRS ; Peck Justice SA ; et al.

BioRxiv : the preprint server for biology [bioRxiv] 2025 Apr 08. Date of Electronic Publication: 2025 Apr 08.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

6
Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff : HER2 IHC scoring concordance in breast cancer.

von Wróbel A ; Vandenberghe M ; Scott M ; et al.

Diagnostic pathology [Diagn Pathol] 2025 Apr 04; Vol. 20 (1), pp. 35. Date of Electronic Publication: 2025 Apr 04.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

7
Communication and resolution programs expose hard-to-hear truths.

von Hickson GB ; Boothman RC ; Krumm AM ; et al.

Frontiers in health services [Front Health Serv] 2025 Mar 04; Vol. 4, pp. 1523363. Date of Electronic Publication: 2025 Mar 04 (Print Publication: 2024).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

8
Human milk immune factors, maternal nutritional status, and infant sex: The INSPIRE study.

von Caffé B ; Blackwell A ; Fehrenkamp BD ; et al.

American journal of human biology : the official journal of the Human Biology Council [Am J Hum Biol] 2023 Nov; Vol. 35 (11), pp. e23943. Date of Electronic Publication: 2023 Jun 26.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

9
Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin.

von Boothman I ; Clayton LM ; McCormack M ; et al.

Frontiers in neuroscience [Front Neurosci] 2023 Sep 08; Vol. 17, pp. 1156362. Date of Electronic Publication: 2023 Sep 08 (Print Publication: 2023).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

10
Microbial communities in freshwater used for hydraulic fracturing are unable to withstand the high temperatures and pressures characteristic of fractured shales.

von Nixon SL ; Plominsky AM ; Hernandez-Becerra N ; et al.

Access microbiology [Access Microbiol] 2023 Apr 21; Vol. 5 (4). Date of Electronic Publication: 2023 Apr 21 (Print Publication: 2023).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

11
Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.

von Dalvi T ; Nørgaard M ; Fryzek JP ; et al.

PloS one [PLoS One] 2023 Apr 11; Vol. 18 (4), pp. e0284037. Date of Electronic Publication: 2023 Apr 11 (Print Publication: 2023).
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

12
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark.

von Hedgeman E ; Nørgaard M ; Dalvi T ; et al.

Cancer epidemiology [Cancer Epidemiol] 2021 Aug; Vol. 73, pp. 101976. Date of Electronic Publication: 2021 Jul 01.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

13
The "Key" or "Critical" Portions of an Operation: Understanding Attending Supervision and Resident Autonomy From a Legal Perspective.

von Williams AM ; Chang EL ; Boothman R ; et al.

Journal of surgical education [J Surg Educ] 2020 Jul - Aug; Vol. 77 (4), pp. 931-938. Date of Electronic Publication: 2020 Mar 12.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

14
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.

von Rizvi NA ; Cho BC ; Reinmuth N ; et al.

JAMA oncology [JAMA Oncol] 2020 May 01; Vol. 6 (5), pp. 661-674.
- Volltextverfügbarkeit prüfen (via ReDI)
- Zur Referenz in PubMed
Merkliste

15
Cytology for PD-L1 testing: A systematic review.

von Gosney JR ; Boothman AM ; Ratcliffe M ; et al.

Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Mar; Vol. 141, pp. 101-106. Date of Electronic Publication: 2020 Jan 13.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

16
Response to Letter to the Editor Titled "The Impact of Patient Characteristics on Tumor Cell PD-L1 Expression in NSCLC Patients".

von Boothman AM ; Walker J

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Sep; Vol. 14 (9), pp. e212-e213.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

17
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.

von Boothman AM ; Scott M ; Ratcliffe M ; et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Aug; Vol. 14 (8), pp. 1390-1399. Date of Electronic Publication: 2019 May 04.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

18
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.

von Zajac M ; Boothman AM ; Ben Y ; et al.

Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2019 Jun; Vol. 143 (6), pp. 722-731. Date of Electronic Publication: 2018 Nov 20.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

19
Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.

von Bujac S ; Del Parigi A ; Sugg J ; et al.

Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2014 Dec; Vol. 5 (2), pp. 471-82. Date of Electronic Publication: 2014 Dec 12.
- View full text via DOI
- Zur Referenz in PubMed
Merkliste

20
Disclosure, apology, and offer programs: stakeholders' views of barriers to and strategies for broad implementation.

von Bell SK ; Smulowitz PB ; Woodward AC ; et al.

The Milbank quarterly [Milbank Q] 2012 Dec; Vol. 90 (4), pp. 682-705.
Merkliste

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag